Actively Recruiting

Age: 25Years - 80Years
All Genders
NCT05518617

Molecular and Functional Imaging in Monogenic PD.

Led by University of Exeter · Updated on 2025-10-07

45

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

In this study, the investigators aim to find a biomarker of Parkinson's disease. This is done using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The findings will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of PD symptoms.

CONDITIONS

Official Title

Molecular and Functional Imaging in Monogenic PD.

Who Can Participate

Age: 25Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to understand and provide signed informed consent
  • Willing and able to comply with scheduled visits, procedures, and lab tests
  • Able to travel to research sites for study procedures
  • For females: either not able to have children (surgically sterile or post-menopausal) or not pregnant and not breastfeeding
  • Agree to use highly effective contraceptive methods if of childbearing potential
  • For sexually active males: agree to use condoms and medically approved contraception during the study and for 3 months after last PET or SPECT procedure
  • Adequate vision and hearing to complete psychological testing
  • Not using medications known to interact with serotonin transmission
  • Willing and able to stop medications interfering with dopamine transporter imaging for at least 5 half-lives before screening
Not Eligible

You will not qualify if you...

  • Lack of capacity to consent
  • Clinical diagnosis of dementia
  • Current use of anticoagulants that prevent safe lumbar puncture
  • Conditions that make lumbar puncture unsafe (e.g., spinal disease, bleeding disorders)
  • Use of drugs interfering with dopamine transporter imaging within 5 months before screening
  • Use of investigational drugs or devices within 60 days before baseline
  • History of cancer within 5 years except non-metastatic basal cell carcinoma
  • Current or recent drug or alcohol abuse
  • Contraindications to MRI (metal implants, metal in body, claustrophobia, severe back pain)
  • Previous MRI showing significant neurological disorder
  • Any other medical or psychiatric condition or lab abnormality that might prevent participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Of Exeter

Exeter, Devon, United Kingdom, EX1 2LU

Actively Recruiting

Loading map...

Research Team

M

Marios Politis, Professor

CONTACT

E

Edoardo de Natale, Dr

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here